Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

152.87 +0.53 (+0.34%)
Streaming Delayed Price Updated: 3:50 PM EDT, Jun 27, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,039,345
Open 153.00
Bid (Size) 152.84 (1)
Ask (Size) 152.88 (3)
Prev. Close 152.34
Today's Range 152.75 - 155.45
52wk Range 105.56 - 175.91
Shares Outstanding N/A
Dividend Yield 3.40%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
AbbVie Stock’s Healthy Yield Makes it a High-Conviction Holding
Between the dividend payouts and the potential price appreciation, ABBV stock could be a pharma-market winner in 2022. 
Via InvestorPlace
Top 3 Dividend Stocks For Any Market
As inflation heats up and the Fed raises interest rates, now is the time to check out AbbVie, Enterprise Product Partners, and NextEra Energy Partners. 
Via Talk Markets

Performance

YTD
+12.88%
+12.88%
1 Month
+1.91%
+1.91%
3 Month
-5.62%
-5.62%
6 Month
+13.73%
+13.73%
1 Year
+35.28%
+35.28%

More News

Read More
ABBVIE INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of AbbVie Inc. - ABBV
From Kahn Swick & Foti, LLC
Via Business Wire
If You Invested $100 In This Stock 5 Years Ago, You Would Have $200 Today
Via Benzinga
AbbVie Whale Trades Spotted
Via Benzinga
Recap of Tuesday's Biotech Catalysts - End of the Day Summary
Via Benzinga
AbbVie Whale Trades Spotted
Via Benzinga
Economic Hurricane Ahead? 7 Profitable Places to Hide Your Money
Via InvestorPlace
Why AbbVie Stock Is Trading Higher Today
Via Benzinga
Jim Cramer Says This Is A Terrific Stock
Via Benzinga
AbbVie - Genmab Present Epcoritamab Data From Lymphoma Trial
Via Benzinga
Consistent Clinical Results Indicate Upside for AbbVie Stock
Via InvestorPlace
The Daily Biotech Pulse: Addex Terminates Parkinson's Study, Expanded Use Of Rhythm's Obesity Drug, FDA Approval For AbbVie's Skyrizi In Crohn's Disease
Via Benzinga
BioMedNewsBreaks – Odyssey Health Inc.’s (ODYY) Novel Drug Candidate Represents a Valuable Asset
Via Investor Brand Network
AbbVie Signs Licensing Deal With Sirona Biochem For Effective New Hydroquinone Alternative
Via Zexprwire
Topics Intellectual Property
Exposures Intellectual Property
AbbVie Whale Trades For June 14
Via Benzinga
5 Pharma Company Analyst Targets and most Bullish Case for each
Via AB Newswire
7 Dividend Stocks to Buy for Your Grandkids
Via InvestorPlace
7 Great ETFs to Buy Now for Momentum in Q2
Via InvestorPlace
3 Dividend Stocks to Buy Now for 20 Years of Income Growth
Via InvestorPlace
If You Invested $100 In This Stock 5 Years Ago, You Would Have $200 Today
Via Benzinga
Johnson & Johnson-AbbVie Partnered Lymphoma Drug Slows Disease Progression, Data Shows
Via Benzinga
Final Deadline Alert - Bronstein, Gewirtz & Grossman, LLC Notifies AbbVie, Inc. (ABBV) Investors of Class Action and Last Few Hours to Actively Participate
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
ABBV FINAL DEADLINE MONDAY: ROSEN, LEADING INVESTOR COUNSEL, Encourages AbbVie Inc. Investors with Losses to Secure Counsel Before Important June 6 Deadline in Securities Class Action - ABBV
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
ABBVIE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against AbbVie, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.